Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 8:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–4 of 4 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Lamivudine Oral Solution Clear all
Completed Phase 3 Interventional Results available

A Study of Pegylated Interferon Alfa-2A in Combination With Lamivudine or Entecavir Compared With Untreated Control Group in Children With Hepatitis B Envelope Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB) in the Immune-Tolerant Phase

NCT02263079
View directory record Official record
Conditions
Pediatric Immuno-Tolerant Chronic Hepatitis B
Interventions
Entecavir, Lamivudine, Pegylated Interferon Alfa-2A
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
3 Years to 17 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
3
States / cities
Kansas City, Missouri • New York, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 23, 2020 · Synced Sep 23, 2026, 8:55 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV

NCT02016924
View directory record Official record
Conditions
Acquired Immune Deficiency Syndrome (AIDS), HIV Infections
Interventions
ATV, DRV, Cobicistat, BR, F/TAF, LPV/r, Third Unboosted Drug, Cobicistat TOS, F/TAF TOS
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
4 Weeks to 17 Years
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
7
States / cities
Long Beach, California • Los Angeles, California • Aurora, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Sep 23, 2026, 8:55 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Phase IV, Open Label, 4-period Cross-over Study to Investigate a Drug Interaction Between Lamivudine and Sorbitol Oral Solutions in Healthy Volunteers

NCT02634073
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
Lamivudine, Sorbitol
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 14, 2017 · Synced Sep 23, 2026, 8:55 PM EDT
Active, not recruiting Phase 3 Interventional

Reducing Vertical Transmission of Hepatitis B in Africa

NCT04704024
View directory record Official record
Conditions
Hepatitis B Infection
Interventions
Tenofovir Disoproxil Fumarate, Lamivudine Oral Solution
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
16 Years to 50 Years · Female only
Enrollment
334 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 23, 2026, 8:55 PM EDT